Clinical Trials Browser

OTHER × Lymphoma, Large-Cell, Anaplastic × Nivolumab × Clear all

NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT07013565 2026-05-20

ACCELERATE

Phase 2 Recruiting

20 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT03075553 2020-04-21

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

12 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Immunoblastic Lymphadenopathy, Mycosis Fungoides, HTLV-I Infections, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma